Enterovirus D68-associated acute respiratory illness - new vaccine surveillance network, United states, July-October, 2017 and 2018
Document Type
Article
Publication Date
3-29-2019
Identifier
DOI: 10.15585/mmwr.mm6812a1; PMCID: PMC6448985
Abstract
In the fall of 2014, an outbreak of enterovirus D68 (EV-D68)-associated acute respiratory illness (ARI) occurred in the United States (1,2); before 2014, EV-D68 was rarely reported to CDC (2,3). In the United States, reported EV-D68 detections typically peak during late summer and early fall (3). EV-D68 epidemiology is not fully understood because testing in clinical settings seldom has been available and detections are not notifiable to CDC. To better understand EV-D68 epidemiology, CDC recently established active, prospective EV-D68 surveillance among pediatric patients at seven U.S. medical centers through the New Vaccine Surveillance Network (NVSN) (4). This report details a preliminary characterization of EV-D68 testing and detections among emergency department (ED) and hospitalized patients with ARI at all NVSN sites during July 1-October 31, 2017, and the same period in 2018. Among patients with ARI who were tested, EV-D68 was detected in two patients (0.8%) in 2017 and 358 (13.9%) in 2018. Continued active, prospective surveillance of EV-D68-associated ARI is needed to better understand EV-D68 epidemiology in the United States.
Journal Title
Morbidity and Mortality Weekly Report
Volume
68
Issue
12
First Page
289
Last Page
290
Recommended Citation
Kujawski SA, Midgley CM, Rha B, et al. Enterovirus D68-Associated Acute Respiratory Illness - New Vaccine Surveillance Network, United States, July-October, 2017 and 2018 [published correction appears in MMWR Morb Mortal Wkly Rep. 2019 Apr 19;68(15):360]. MMWR Morb Mortal Wkly Rep. 2019;68(12):277-280. Published 2019 Mar 29. doi:10.15585/mmwr.mm6812a1
COinS
Comments
Erratum in